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SUMMARY
The relationship, in 539 individuals infected with the human immunodeficiency virus (HIV),
between two prognostic markers, the CD4 count and beta-2-microglobulin (B2M), and the
development of the acquired immunodeficiency syndrome (AIDS) and death was investigated.
Cox proportional hazards models were used to determine the risk of AIDS or death. In a
multivariate model which adjusted for demographic factors and treatment, the most recent
measurements of B2M (relative hazard (RH) 1±37 per g}l higher) and CD4 count (RH 2±17 per
log-unit lower) were both significantly associated with the development of AIDS. Similarly, in
a multivariate model which additionally adjusted for the development of AIDS as a time
dependant covariate, there was a strong relationship with risk of death for the most recent
measurements of B2M (RH 1±34 per g}l higher), and CD4 lymphocyte count (RH 1±91 per log-
unit lower). A difference in the level of B2M could be used among patients with similar CD4
counts as an indicator of increased risk of progression to AIDS or death. Using the most
recent values of these markers provides a better estimate of the risk of AIDS or death,
compared to the more common method of analysis, where baseline values of the markers are
used.
INTRODUCTION
In patients infected with the human immunodeficiency
virus (HIV), both serum beta-2-microglobulin (B2M),
a sub-unit of the class I major histocompatibility
complex found on the surface of nucleated cells and
thought to reflect the degree of immune activation [1],
and CD4 lymphocyte counts, have been shown to
predict the development of AIDS both individually
and in combination [2–8]. The association between
CD4 lymphocyte counts and death in patients infected
with HIV has also been shown [10–12], but the
relationship between B2M and death has been
explored less thoroughly [13].
In clinical practice, HIV positive patients without
AIDS tend to be seen every few months and markers
such as the CD4 count are used to assess whether or
not a patient is at risk of progressing to AIDS before
their next visit, and to help determine an appropriate
time to start therapy (e.g. when the CD4 count falls
below 200}mm$). Most studies considering the re-
lationship between markers and disease progression
have considered a single value of the prognostic
markers at some arbitrary baseline to calculate the
subsequent risk of AIDS or death, usually over a
follow-up period measured in years [3, 5–9]. To date,
few studies have assessed the predictive value of the
CD4 count when all measurements taken during
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follow-up are accounted for [14–16], and it remains to
be demonstrated that B2M and CD4 count inde-
pendently predict the risk of AIDS or death in this
more clinically relevant situation.
We took advantage of a large patient group seen
regularly at the Royal Free Hospital in whom B2M
and CD4 counts are measured at regular intervals, to
determine if both B2M and CD4 counts are in-
dependent predictors of AIDS and death using time-
updated measurements. We also illustrate and discuss
the different results that would be obtained if only
baseline values of the prognostic markers were used.
MATERIALS AND METHODS
Patients
All patients seen at the Ian Charleson Day Centre
(ICDC), the outpatient facility for patients infected
with HIV at the Royal Free Hospital, London, were
eligible for inclusion in this study. Of these, all
patients with greater than one month of follow-up and
for whom at least one CD4 count and B2M
measurement were available were included. Diagnosis
of AIDS was made according to the Centers for
Disease Control 1987 criteria [17]. Date of birth,
exposure category, ethnic origin, CD4 lymphocyte
counts, B2M levels, and date of death were obtained
from the HIV}AIDS unit database. Where possible,
dates of death for patients lost to follow-up were
obtained from the Communicable Disease Surveil-
lance Centre. The dates of starting antiretrovirals
(zidovudine, didanosine or zalcitabine) and prophy-
laxis for Pneumocystis carinii pneumonia (PCP),
(nebulized pentamidine, cotrimoxazole, dapsone or
clindamycin) were obtained by a retrospective search
through all patient notes.
Laboratory methods
CD4 analysis
A whole blood lysis method was used and the
percentage CD4 lymphocytes was expressed as ab-
solute CD4 counts on the basis of lymphocyte counts.
A monoclonal antibody, RFT4, was used, as described
previously [17]. More recently, absolute CD4 counts
have been obtained directly in an ORTHO Cytoron-
Absolute flow-cytometer (ORTHO Diagnostics, High
Wycombe, UK). Quality control was routinely
monitored in the UK National External Quality
Assurance Scheme. A median of 10 CD4 lymphocyte
counts per person were available (90% range 2–39), at
a median time interval of 1±3 months (90% range
0±3–5±3 months).
Beta-2-microglobulin
Beta-2-microglobulin was measured on fresh serum
samples, using a commercial radial immunodiffusion
(RID) method (NanaRID, Binding Site Ltd, UK).
The measurements were routinely monitored in the
UK National External Quality Assurance Scheme. A
median of 7 measurements (90% range 1–21) of B2M
were made during follow-up, at a median time interval
of 1±4 months (90% range 0±4–5±1 months).
Statistical methods
Disease progression to AIDS or death according to
the lowest CD4 count recorded was analysed using
Kaplan-Meier curves [19] ; this assumes that CD4
lymphocyte count was a monotonic decreasing func-
tion of time. The prognostic markers studied, CD4
counts and B2M, were modelled as time-dependant
covariates in Cox proportional hazards models. This
method models the risk of an event using the latest
available value of the marker at the time of each event.
Inevitably the marker values fluctuate, which may be
due to laboratory techniques or due to changes in the
health of the patient. This tends to result in an
underestimation of the relative hazard and wider
confidence intervals [20]. Treatment with anti-
retroviral drugs or PCP prophylaxis was also included
in the model as time dependant covariates. Binary
variables were created which took the value of zero
before a patient began treatment, and switched to one
thereafter. When studying the association between
B2M, CD4 counts and risk of death, the development
of AIDS was additionally fitted as a time dependant
covariate. Various transformations (logarithmic,
square root etc.) of both CD4 and B2M were
performed to determine the best fitting model. Further
models which considered only baseline values of the
prognostic markers were also fitted using Cox pro-
portional hazards models. There was no evidence that
the assumption of proportional hazards did not hold
(P" 0±05). Interactions between demographic
variables and the immunological markers were also
included in the model, but their inclusion did not
result in a significant improvement in fit. Patients were
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followed-up to the date of last follow-up, or 31
August 1994, whichever occurred first. Excluding
patients who had died, only 40 patients (7±4%) had
not been seen for 12-months at 31 August 1994. All
statistical analyses were carried out using Statistical
Analysis Software (SAS) [21], and all tests of
significance were two-sided.
RESULTS
A total of 539 patients without AIDS at baseline were
included in this analysis. The median total follow-up
time, from first visit, when the baseline values of CD4
counts and B2M were established, to death or last
visit was 21±1 months (90% range 2±8–60±2 months),
during which time 54 patients (10±0%) died. The
median age at first visit was 30±6 years (90% range
22±0–47±0 years) ; the male patients were significantly
older than the females (median ages 31±1 and 28±8
respectively, P! 0±0001 Wilcoxon). Table 1 illustrates
the demography of the population, together with the
median baseline values of both CD4 lymphocyte
counts and B2M, all of which were measured within 3
months of a patient’s first visit to the hospital. The
majority of the patients were male (448, 83±1%), and
homosexual or bisexual (429, 79±6%). As can be seen
from Table 1, Caucasian patients had significantly
higher median CD4 counts at first visit than patients
from other ethnic groups (P¯ 0±004, Wilcoxon). In
addition, there were statistically significant differences
in median baseline values of CD4 count and B2M
between different exposure groups; intravenous drug
users (IDU) presented with the highest CD4 counts
(P¯ 0±03, Wilcoxon) while homosexuals or bisexuals
presented with the lowest values of B2M (P¯ 0±01,
Wilcoxon). Patients who were aged more than 35 at
baseline had significantly lower CD4 lymphocyte
counts and higher levels of B2M (P¯ 0±004 and P!
0±0001 respectively, Wilcoxon).
One hundred and thirty-one patients (24±3%)
developed AIDS over a median follow-up time of 18±4
months (90% range 1±8–56±5 months). The initial
AIDS defining diagnoses made include 31 of oeso-
phageal candidiasis (23±7%), 22 of PCP (16±8%), 20
of Kaposi’s sarcoma (15±3%) and 10 of HIV wasting
syndrome (7±6%). At the start of this study, 18
patients (3±3%) had already commenced treatment
with zidovudine and 17 patients (3±2%) were receiving
primary PCP prophylaxis. During subsequent follow-
up, 155 patients (28±8%) commenced treatment with
antiretrovirals, the majority of whom were treated
with zidovudine, a similar number of patients (172,
31±9%) started PCP prophylaxis.
Figure 1 illustrates the Kaplan–Meier progression
rates to AIDS and death according to the lowest CD4
count measured. This clearly shows the relationship
between decreasing CD4 counts and the risk of AIDS
and death. The risk of AIDS remained small until a
CD4 count of 200}mm$ was reached. Kaplan–Meier
estimates suggest that 9% of patients will have a
diagnosis of AIDS when the CD4 lymphocyte count
has declined to 200}mm$. After this time the risk of
AIDS increased exponentially. Similarly, the risk of
death was negligible until the CD4 count fell to
50}mm$, but again, increased dramatically after this
time.
Table 2 shows the univariate relative risks for the
development of AIDS associated with age, sex, ethnic
origin, exposure category, treatment, B2M and CD4
lymphocyte count. In the univariate analysis, both a
higher B2M measurement and lower CD4 counts
during follow-up were associated with a significantly
raised risk of AIDS (relative hazard (RH) per g}l
higher and 2±50 per log-unit lower respectively ; P!
0±0001 for both). Treatment and age were also
significant predictors for the development of AIDS;
there was a 36% increase in risk of AIDS for every 10
year higher age (RH 1±36; 95% confidence interval
(CI) 1±12–1±63, P¯ 0±002) and a 110% increased risk
of AIDS in those patients who started antiretroviral
treatment (RH 2±10, 95% CI 1±46–3±02, P! 0±0001).
B2M and CD4 count were correlated at baseline
(correlation coefficient ®0±385, P! 0±0001), thus
patients with high B2M levels had lower CD4 counts
and it is essential to adjust for these at the same time.
Age, ethnic group and exposure category were also
related to each other, thus a multivariate analysis was
needed to clarify the strongest independant effects. In
addition to mutually adjusting for B2M and CD4
lymphocyte counts, the multivariate analysis also
adjusted for age, treatment, and demographic factors
such as gender and ethnic origin. These results showed
that B2M and CD4 counts were independant markers
for the development of AIDS, and patients with
similar CD4 counts but in whom the B2M level was
higher were at an increased risk of developing AIDS.
Patients who are treated with antiretrovirals were at a
reduced risk of AIDS in the multivariate analysis (RH
0±56; 95% Cl 0±29–1±05, P¯ 0±07), which indicates
that despite the fact that patients who started
treatment were more ill (as measured by low CD4
counts and high B2M levels) there was some reduction
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Table 1. A description of HIV positive patients at the Royal Free Hospital
Total
CD4 count at baseline B2M at baseline
AIDS Death Mean Median Mean Median
No. % No. No. (s.d.) (90% range) P* (s.d.) (90% range) P*
All patients 539 100 131 54 434 (287) 400 (40–910) n.a. 3±1 (1±7) 2±9 (1±8–5±1) n.a.
Gender
Male 448 83±1 115 47 440 (289) 412 (40–900) 0±2 3±1 (1±1) 2±9 (1±9–5±1) 0±2
Female 91 16±9 16 7 405 (276) 380 (30–1010) — 3±0 (0±9) 2±7 (1±7–4±7)
Age group
/ 25 85 15±8 16 6 489 (380) 410 (90–1000) 0±004 2±7 (0±8) 2±7 (1±6–3±8) 0±0001
26–35 306 57±1 68 24 450 (274) 420 (40–920) — 3±1 (1±1) 2±8 (1±9–5±1) —
" 35 148 27±5 47 24 369 (237) 356 (40–750) — 3±4 (1±1) 3±2 (2±1–5±2) —
Ethnic origin
Caucasian 429 79±6 110 47 452 (297) 420 (50–940) 0±0001 3±2 (1±1) 2±9 (1±9–5±1) 0±07
Other 110 20±4 21 7 363 (228) 350 (30–740) — 2±9 (0±9) 2±8 (1±7–4±6) —
Exposure category
Homo}bisexual 345 64±0 98 41 440 (266) 420 (50–910) 0±03 3±1 (1±0) 2±8 (1±8–5±0) 0±01
IDU 48 8±9 11 3 486 (271) 495 (20–880) — 3±3 (1±1) 3±1 (1±9–5±1) —
Heterosexual 97 18±0 19 7 371 (246) 350 (30–900) — 3±0 (1±0) 2±8 (1±7–4±7) —
Other 49 9±1 3 3 461 (456) 350 (120–1110) — 3±5 (1±3) 3±4 (2±1–5±3)
* P, P-value for testing for differences between groups using Wilcoxon test.
 n.a., not applicable.
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Fig. 1. Kaplan-Meier progression rates to AIDS and
death according to the lowest CD4 count measured. (V)
progression to AIDS, (­) progression to death.
in the risk of AIDS in patients who start treatment
with antiretrovirals.
Table 3 presents similar statistics to Table 2, with
death, rather than AIDS, as an endpoint. The
multivariate analysis has adjusted for the same
variables as above, and in addition this model has
been adjusted for the development of AIDS as a time
dependant variable. The results show that both CD4
count and B2M were strong prognostic markers (RH
1±91 per log-unit lower and 1±34 per g}l higher ; P!
0±0001 and P¯ 0±004 respectively). In addition, the
development of AIDS was a strong predictor of
death; patients who develop AIDS were nearly 27
times more likely to die than those patients who had
not developed AIDS, even after adjustment for CD4
lymphocyte counts and B2M (RH 26±59; 95% Cl
5±06–139±68, P! 0±0001). In contrast to the data
shown in Table 2, increasing age significantly
increased the risk of death, even after adjustment for
all other variables (RH 1±56; 95% Cl 1±09–2±24, P¯
0±02).
All the analyses presented above concentrate on the
role of the most recent CD4 and B2M measurement
for predicting the development of AIDS or death. Of
interest is how this predictive value changed if only the
baseline measurements were used to predict the
outcome. Table 4 shows the effect of incorporating
only baseline values of the laboratory markers on the
estimates of the relative hazard. Once again, the
multivariate model was adjusted for the same
variables as discussed above for Table 2. Model 1
shows the relative hazards from Table 2 for com-
parison. Model 2 shows the results which would have
been obtained if only one value of each marker were
available at the patient’s baseline visit. In the
univariate model, the relative hazard of AIDS or
death associated with either B2M or CD4 lymphocyte
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Table 2. Univariate and multivariate relative hazards of AIDS
Variables modelled using Cox
Univariate Multivariate
proportional hazards model RH (95% Cl) P-value RH (95% Cl) P-value
B2M (per g}l increase)* 1±79 (1±56–2±05) 0±0001 1±37 (1±13–1±65) 0±0012
CD4 (per log decrease)* 2±50 (2±21–2±83) 0±0001 2±17 (1±77–2±66) 0±0001
age (per 10 yr increase) 1±36 (1±12–1±63) 0±002 1±12 (0±82–1±51) 0±5
PCP prophylaxis* 3±44 (2±12–5±33) 0±0001 0±72 (0±51–1±78) 0±6
ARV treatment* 2±10 (1±46–3±02) 0±001 0±56 (0±29–1±05) 0±07
Gender
Female 0±64 (0±38–1±06) 0±08 0±64 (0±27–1±52) 0±3
Exposure category
IDU 0±95 (0±49–1±83) 0±9 1±11 (0±45–2±70) 0±8
Heterosexual 0±80 (0±49–1±31) 0±4 1±11 (0±46–2±39) 0±8
Other 1±00 (0±57–1±76) 1±0 1±04 (0±46–2±39) 0±9
Ethnic origin
Caucasian 1±54 (0±97–1±03) 0±07 0±60 (0±30–1±22) 0±2
* Variables were modelled as time dependant covariates.
 Relative risk compared to males.
 Relative risk compared to homosexual}bisexuals.
 Relative risk compared to all other ethnic groups combined.
Table 3. Univariate and multivariate relative hazards of death
Variables modelled using Cox
Univariate Multivariate
proportional hazards model RH (95% Cl) P-value RH (95% Cl) P-value
B2M (per g}l increase)* 2±06 (1±76–2±41) 0±0001 1±34 (1±10–1±64) 0±0004
CD4 (per log decrease)* 2±99 (2±36–3±79) 0±0001 1±91 (1±40–2±62) 0±0001
age (per 10 yr increase) 1±76 (1±34–2±31) 0±0001 1±56 (1±09–2±24) 0±02
PCP prophylaxis* 5±37 (2±72–10±63) 0±0001 0±60 (0±24–1±50) 0±3
ARV treatment* 2±99 (1±52–5±86) 0±0015 0±59 (0±23–1±49) 0±3
Gender
Female 0±71 (0±62–1±57) 0±4 1±65 (0±52–5±28) 0±4
Exposure category
IDU 0±91 (0±28–2±99) 0±9 0±76 (0±18–3±27) 0±7
Heterosexual 0±76 (0±34–1±72) 0±5 0±86 (0±57–6±02) 0±3
Other 1±56 (0±73–3±44) 0±2 2±02 (0±80–5±12) 0±1
Ethnic origin
Caucasian 1±54 (0±97–5±26) 0±06 2±50 (0±75–8±33) 0±1
Diagnosis of AIDS* 50±49 (17±38–146±73) 0±0001 26±59 (5±06–139±68) 0±0001
* Variables were modelled as time dependant covariates.
 Relative risk compared to males.
 Relative risk compared to homosexual}bisexuals.
 Relative risk compared to all other ethnic groups combined.
count dropped towards one, indicating that some
important information has been lost. In the multi-
variate models of the risk of AIDS or death the
prognostic value of the B2M appears similar to that
obtained when values were updated over time, whilst
that of the CD4 count is much reduced. This does not
necessarily imply that measuring B2M throughout
follow-up does not provide any additional infor-
mation as Model 2 is under adjusted for the risk of
AIDS or death associated with the CD4 count. A
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Table 4. Univariate and multivariate relative hazards of AIDS and death using baseline values of the
prognostic markers
Univariate Multivariate
RH (95% Cl) P-value RH (95% Cl) P-value
Progression to AIDS
Model 1. CD4 and B2M time-updated covariates
B2M (per g}l increase) 1±79 (1±56–2±05) 0±0001 1±37 (1±13–1±65) 0±0012
CD4 (per log decrease) 2±50 (2±21–2±83) 0±0001 2±17 (1±77–2±66) 0±0001
Model 2. CD4 and B2M fixed at baseline
B2M (per g}l increase) 1±51 (1±38–1±66) 0±0001 1±42 (1±25–1±60) 0±0001
CD4 (per log decrease) 1±96 (1±74–2±21) 0±0001 1±62 (1±37–1±90) 0±0001
Progression to death
Model 1. CD4 and B2M time-updated covariates
B2M (per g}l increase) 2±06 (1±76–2±41) 0±0001 1±34 (1±10–1±64) 0±0004
CD4 (per log decrease) 2±99 (2±36–3±79) 0±0001 1±91 (1±40–2±62) 0±0001
Model 2. CD4 and B2M fixed at baseline
B2M (per g}l increase) 1±71 (1±50–1±95) 0±0001 1±55 (1±23–1±94) 0±0001
CD4 (per log decrease) 1±85 (1±52–2±25) 0±0001 1±48 (1±16–1±76) 0±0001
multivariate model which accounts for the baseline
value of B2M and updated CD4 counts revealed that
the risk of AIDS increased by 24% (RH 1±24; 95% Cl
1±13–1±36, P! 0±0001) for a 1 g}l higher B2M value
and the risk of death increased by 18% (RH 1±18;
95% Cl 1±04–1±34, P¯ 0±014). Clearly, using updated
values of both prognostic markers provides valuable
information about the risk of AIDS or death.
DISCUSSION
We have demonstrated that in HIV positive indi-
viduals the most recently measured CD4 lymphocyte
count and B2M level independently predicted AIDS
and death. Previous studies have illustrated that the
CD4 count is an important prognostic marker when
modelled as a time-updated variable [4, 14–16], but to
our knowledge ours is the first which illustrates that
the latest value of B2M provides extra information in
addition to that provided by the CD4 count in this
context. In common with Kerlikowske and colleagues
[13], we have also demonstrated in a much larger and
more heterogeneous patient group that B2M is also a
prognostic marker for death.
It is well documented, mainly in groups of patients
with haemophilia, that there is an association between
increasing age and progression to AIDS, with older
individuals progressing to AIDS more rapidly [22–24].
After adjustment for various demographic variables
and the markers studied, we did not find a significant
relationship between age and progression to AIDS.
This may be due, in part, to the exposure categories of
our patient group. However, even after adjustment for
all other factors, the relationship between age and
death was statistically significant, in common with
some studies that have looked at the relationship
between age and death in patients with AIDS [25–26].
In the univariate analyses, we found an increased
risk of both AIDS and death for those patients treated
with antiretrovirals or who had commenced PCP
prophylaxis, which reflects that treatment is given to
patients with deteriorating health. However, the
results of the multivariate analysis showed that both
antiretroviral treatment and prophylaxis for PCP
were associated with a decreased risk of both AIDS
and death, although these were not statistically
significant due to the smaller power of our study,
consistent with the findings that both treatments can
reduce the risk of progression to AIDS and prolong
survival [27–28].
Several other ‘activation markers ’, such as neop-
terin and IgA have also been proposed as markers of
disease progression [6, 14, 29–30]. Beta-2-micro-
globulin and neopterin have been shown to be highly
correlated; both appear to predict disease progression
equally well, but one does not provide any additional
information on top of that already provided by the
other [27, 29]. The ease of measurement of neopterin
in urine often makes it more acceptable for use in
routine clinical monitoring, particularly in Africa
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where limited resources and facilities are available
[31]. However, all these activation markers have been
shown to be highly correlated with plasma viral load
[32], and it remains to be seen whether they will
predict disease progression in addition to viral load
and CD4 lymphocyte count.
We have shown that the apparent prognostic value
of a laboratory marker differs when only a single
measurement of the marker is available at some
arbitrary baseline. This is because both the CD4 count
and B2M levels change during infection and to a
different extent in different patients, such that values
at the time of the baseline measurement become a
relatively imprecise measure of the values at the time
of AIDS or death. The two methods of analysis have
different interpretations and clinical significance. To
assess patient prognosis over the next 3 months or so,
more information is provided by the time-updated
analysis, in contrast to using baseline measurements,
where the question of longer term prognosis is
addressed. The difference between these models is not
often highlighted; Spijkerman and colleagues [33]
recently showed that the relationship between
syncytium inducing phenotype of HIV and AIDS was
no longer significant after adjustment for the CD4
count as a continuous time dependant covariate, and
attributed this to differences in rate of CD4 decline
between patients infected with syncytium inducing
and non-syncytium inducing phenotypes.
There are several issues to consider in interpreting
the results of this analysis. Bias may arise if patients
lost to follow-up are not lost randomly; there was no
evidence that this was the case. CD4 lymphocyte
counts have been measured more regularly than B2M
in our patient group, and although the time between
successive measurements was not dissimilar for both
markers this may have biased our results to show a
weaker relationship between B2M and CD4 count
than actually exists. However, both B2M and CD4
count were shown to be strong independent prognostic
markers for AIDS and death.
To conclude, we have shown that the latest
measurement of B2M provides significant prognostic
information in addition to that provided by the latest
CD4 count. Thus among patients with similar CD4
counts, those with higher levels of B2M are at an
increased risk of disease progression over the fol-
lowing few months. We have also illustrated that B2M
is an independent prognostic marker for death in
patients infected with HIV, and thus that the
continued measurement of these markers can help
with patient monitoring. Further, we have discussed
the results of modelling baseline values of prognostic
markers ; future markers which are proposed to
predict the development of AIDS independently of
the CD4 count should additionally be modelled as
time-updated covariates to determine if the most
recent measurement adds to the information provided
by the latest value of the CD4 lymphocyte count.
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